Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease

  1. Todd A. Lee, PharmD, PhD;
  2. A. Simon Pickard, PhD;
  3. David H. Au, MD, MS;
  4. Brian Bartle, MPH; and
  5. Kevin B. Weiss, MD, MPH, MS
  1. From the Hines Veterans Affairs Hospital, Hines, Illinois; Northwestern University Feinberg School of Medicine, Chicago, Illinois; University of Illinois at Chicago, Chicago, Illinois; Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington; and the American Board of Medical Specialties, Evanston, Illinois.
    1. Figure 1.
      View larger version:
      Figure 1. Study flow diagram.

      COPD = chronic obstructive pulmonary disease.

    2. Figure 2.
      View larger version:
      Figure 2. Risk for mortality associated with respiratory medications in the sensitivity analyses for each study end point.

      Bars indicate 95% CIs. CHF = chronic heart failure; ICS = inhaled corticosteroid; IPRA = ipratropium; LABA = long-acting β-agonist; SABA = short-acting β-agonist; THEO = theophylline.

    Responses to this article

    « Previous | Next Article »Table of Contents